Displaying drugs 15451 - 15475 of 16216 in total
Brogidirsen
Brogidirsen is under investigation in clinical trial NCT05996003 (NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)).
Investigational
Venanprubart
Venanprubart is under investigation in clinical trial NCT05781451 (Anti-btla Agonist Therapy in Subjects With Primary Sjogren's Syndrome).
Investigational
Zigakibart
Zigakibart is under investigation in clinical trial NCT05852938 (A Study of BION-1301 in Adults With Iga Nephropathy).
Investigational
Verzistobart
Verzistobart is under investigation in clinical trial NCT06056895 (Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma).
Investigational
Vamikibart
Vamikibart is under investigation in clinical trial NCT05642312 (A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema).
Investigational
Narlumosbart
Narlumosbart is under investigation in clinical trial NCT06314698 (Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease).
Investigational
Insulin efsitora alfa
Insulin efsitora alfa is under investigation in clinical trial NCT05662332 (A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)).
Investigational
Elebsiran
Elebsiran is under investigation in clinical trial NCT05461170 (SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.).
Investigational
Bevonescein
Bevonescein is under investigation in clinical trial NCT06227585 (Feasibility Study- REVEAL 475 for Bevonescein-assisted Nerve Visualization in Head & Neck Surgery).
Investigational
Rivogenlecleucel
Investigational
Xanthium sibiricum fruit
Investigational
KT-A261
KT-A261 is an adeno-associated viral vector serotype 2 (AAV2) encoded to express adalimumab. It is being investigated for the treatment of noninfectious uveitis.
Investigational
A-16L
Investigational
ND1251
ND1251 is an orally active phosphodiesterase-4 (PDE4) inhibitor, a mechanism clinically proven to play a role in alleviating symptoms of depression. ND1251 is a very potent compound with a large safety margin. ND1251 may also have applications in other disorders, such as Alzheimer's disease, mild cognitive impairment, multiple sclerosis and...
Investigational
Matched Description: … applications in other disorders, such as Alzheimer's disease, mild cognitive impairment, multiple sclerosis and …
5-(4-Methoxyphenoxy)-2,4-Quinazolinediamine
Experimental
SB220025
Experimental
3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine
Experimental
3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
Experimental
ZK-805623
Experimental
Displaying drugs 15451 - 15475 of 16216 in total